Edgar Charles, M.D.
Clinical Development Lead, pegylated FGF21
Edgar leads clinical development for BMS-986036, Bristol-Myers Squibb’s pegylated FGF21 asset. He is responsible for global clinical development of BMS-986036, as well for contributing to the development strategy for other liver fibrosis assets. Edgar joined BMS in 2015.
As leader of the clinical development team, Edgar sets therapeutic strategy, defines clinical plans, and designs Phase 0-3 trials.
Prior to joining BMS, Edgar spent 10 years at Rockefeller University as an Assistant Professor and an Instructor in Clinical Investigation, leading a basic science and translational research program to understand the mechanisms of virus-induced autoimmunity in humans. Edgar’s research identified and functionally characterized a novel B cell subset responsible for human autoimmunity. During his time at Rockefeller, Edgar conducted post-doctoral virology and immunology research, and served as a member or chairman for several hospital committees. Edgar also practiced medicine at Manhattan Veterans Administration Hospital and Bellevue Hospital. After Rockefeller, Edgar joined Merck Research Laboratories, where he led infectious disease strategy in Emerging Markets and served as a global clinical lead for hepatitis C virus therapies. He subsequently came to BMS to work on liver fibrosis, including nonalcoholic steatohepatitis.
Edgar received his MD from University of Alabama School of Medicine, and later, his MSc in Clinical and Translational Investigation at Rockefeller University. He completed his Residency in Internal Medicine and Fellowship in Infectious Diseases at New York University School of Medicine. Edgar has published and presented in the fields of virology, immunology, infectious diseases, autoimmunity and fibrosis, including his recent presentation of data from one of the company’s assets in liver fibrosis.
Interests and Expertise
While at Rockefeller, Edgar conducted research in the laboratory of Charles M. Rice, PhD., and he was a member of the lab that developed the first system for replicating hepatitis C virus in vitro. Edgar was also Rockefeller University’s Chief Clinical Scholar, and his clinical research mentor was Barry S. Coller, MD, who invented abciximab, a monoclonal antibody targeting platelet glycoprotein IIb/IIIa which has been in clinical use for over 20 years. Edgar cites these early experiences as foundational for his future career in the biopharmaceutical industry.
What Edgar finds most exciting in his current role is the opportunity to work on everything from basic science to late stage development; he enjoys contributing to the process by which theoretical ideas progress into practical medicines with the potential to help patients.
Edgar believes in paying forward the mentorship he received from Drs. Rice, Coller and others early in his career, and aims to pass along the wisdom his mentors shared with him. In particular, Edgar enjoys supporting colleagues making the transition from academics to industry, as he did.
Outside of work, Edgar is most often outdoors hiking or camping with his family, including three young children.